CTOs on the Move

Health Interactions

www.healthinteractions.com

 
Health Interactions is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

CRI Worldwide

CRI Worldwide is a Clementon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ventiv Health

Ventiv Health is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tegria

At Tegria, we believe that the right technology and tools can help make care more effective for more people. Launched in 2020 with support from Providence, one of the country`s largest health systems, Tegria combines innovative technologies and services to create powerful solutions that simplify healthcare for everyone involved. We built Tegria to make a difference, not only for our customers, but for our communities. We deliver complete solutions to streamline the process of receiving and delivering care, from first visit to follow-up and beyond.

NutriSavings

NutriSavings mission is to reduce the cost of healthcare by educating employees on healthy eating and rewarding good food choices with savings at the supermarket, grocery store, or farmers market. NutriSavings is a joint venture between Edenred (NYSE Euronext), the world leader in corporate services, and SavingStar, the only national fully digital grocery savings service in the US.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.